These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30950099)

  • 1. Influence of azole antifungal drugs on blood tacrolimus levels after switching from intravenous tacrolimus to once-daily modified release tacrolimus in patients receiving allogeneic hematopoietic stem cell transplantation.
    Mimura A; Yamaori S; Ikemura N; Katsuyama Y; Matsuzawa N; Ohmori S
    J Clin Pharm Ther; 2019 Aug; 44(4):565-571. PubMed ID: 30950099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus blood concentration increase depends on administration route when combined with voriconazole in pediatric stem cell transplant recipients.
    Utano T; Kato M; Osumi T; Shioda Y; Kiyotani C; Terashima K; Tomizawa D; Matsumoto K; Yamatani A
    Pediatr Transplant; 2020 Feb; 24(1):e13619. PubMed ID: 31820535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus Concentration after Letermovir Initiation in Hematopoietic Stem Cell Transplantation Recipients Receiving Voriconazole: A Retrospective, Observational Study.
    Hikasa S; Shimabukuro S; Osugi Y; Ikegame K; Kaida K; Fukunaga K; Higami T; Tada M; Tanaka K; Yanai M; Kimura T
    Int J Med Sci; 2020; 17(7):859-864. PubMed ID: 32308538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.
    Yamashita T; Fujishima N; Miura M; Niioka T; Abumiya M; Shinohara Y; Ubukawa K; Nara M; Fujishima M; Kameoka Y; Tagawa H; Hirokawa M; Takahashi N
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):111-8. PubMed ID: 27217047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation.
    Peksa GD; Schultz K; Fung HC
    J Oncol Pharm Pract; 2015 Dec; 21(6):409-15. PubMed ID: 24938293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Gayle AA; Nobori T; Katayama N; Okuda M
    Ther Drug Monit; 2015 Oct; 37(5):581-8. PubMed ID: 25565672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of azole antifungal agents on the anticoagulant activity of warfarin.
    Yamamoto H; Habu Y; Yano I; Ozaki J; Kimura Y; Sato E; Shida A; Fukatsu S; Matsubara K
    Biol Pharm Bull; 2014; 37(12):1990-3. PubMed ID: 25451849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals.
    Atiq F; Hameli E; Broers AEC; Doorduijn JK; Van Gelder T; Andrews LM; Koch BCP; Versmissen J; de Winter BCM
    Eur J Clin Pharmacol; 2018 Jun; 74(6):767-773. PubMed ID: 29500599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation.
    Suetsugu K; Ikesue H; Miyamoto T; Shiratsuchi M; Yamamoto-Taguchi N; Tsuchiya Y; Matsukawa K; Uchida M; Watanabe H; Akashi K; Masuda S
    Int J Hematol; 2017 Mar; 105(3):361-368. PubMed ID: 27822915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus dose modification in patients receiving concomitant isavuconazole after hematopoietic stem cell transplantation.
    Trifilio S; Rubin H; Monacelli A; Mehta J
    J Oncol Pharm Pract; 2021 Jun; 27(4):857-862. PubMed ID: 32659173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous Infusion of Fentanyl Has No Effect on Blood Concentration of Tacrolimus in Patients Receiving Hematopoietic Stem-Cell Transplantation.
    Ishiwata Y; Nagata M; Kiuchi S; Ippongi C; Takeda H; Takahashi H
    Ther Drug Monit; 2021 Oct; 43(5):688-691. PubMed ID: 33298744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal.
    Nakashima T; Inamoto Y; Aoki J; Ito A; Tanaka T; Kim SW; Hashimoto H; Fukuda T; Furukawa T
    Int J Hematol; 2022 Feb; 115(2):158-162. PubMed ID: 35088349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics for once-daily modified release formulation of tacrolimus hydrate in unrelated hematopoietic stem cell transplantation.
    Yano S; Mori S; Saito T; Yokoyama H; Machishima T; Shimada T; Yahagi Y; Sugiyama K; Ogasawara Y; Takahara S; Kasama K; Katsube A; Kamiyama Y; Suzuki K; Inui Y; Usui N; Aiba K; Yamashita T
    Ann Hematol; 2015 Mar; 94(3):491-6. PubMed ID: 25325985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment with voriconazole combined with amphotericin B-liposome for fluconazole-resistant pulmonary cryptococcosis after renal transplantation.
    Fujioka K; Nagai T; Kinoshita Y; Urushihara M; Hamasaki Y; Shishido S; Kagami S
    CEN Case Rep; 2019 Nov; 8(4):261-265. PubMed ID: 31161376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change of the blood concentration of tacrolimus after the switch from fluconazole to voriconazole in patients receiving allogeneic hematopoietic stem cell transplantation.
    Kawazoe H; Takiguchi Y; Tanaka H; Fukuoka N; Ohnishi H; Ishida T; Houchi H
    Biol Pharm Bull; 2006 Dec; 29(12):2528-31. PubMed ID: 17142996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug interactions of tacrolimus with letermovir and azole antifungals following hematopoietic stem cell transplantation: A retrospective observational analysis.
    Shinogi Y; Hirai T; Ishibashi M; Ino K; Tawara I; Iwamoto T
    Pharmacol Res Perspect; 2023 Aug; 11(4):e01120. PubMed ID: 37530504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of
    Suetsugu K; Mori Y; Yamamoto N; Shigematsu T; Miyamoto T; Egashira N; Akashi K; Masuda S
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The Application Study of Voriconazole and Its Metabolites Concentration Monitoring in Allogeneic Hematopoietic Stem Cell Transplantation Patients].
    Wang HC; Wang L; Li M; Shi L; Sun HH; Liu HX; Ou HL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):945-951. PubMed ID: 38926993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influential Factors and Efficacy Analysis of Tacrolimus Concentration After Allogeneic Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major.
    Li C; Lu J; Zhou S; Wei Y; Lv C; Liu T; Wu Y; Wu D; Qi J; Cai R
    Pharmgenomics Pers Med; 2021; 14():1221-1237. PubMed ID: 34594128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Katayama N; Okuda M
    Clin Ther; 2011 Aug; 33(8):1077-80. PubMed ID: 21802143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.